Monogenic diabetes: a gateway to precision medicine in diabetes
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Monogenic diabetes refers to diabetes mellitus (DM) caused by a mutation in a single gene and accounts for approximately 1%-5% of diabetes. Correct diagnosis is clinically critical for certain types of monogenic diabetes, since the appropriate treatment is determined by the etiology of the disease (e.g., oral sulfonylurea treatment of HNF1A/HNF4A-diabetes vs. insulin injections in type 1 diabetes). However, achieving a correct diagnosis requires genetic testing, and the overlapping of the clinical features of monogenic diabetes with those of type 1 and type 2 diabetes has frequently led to misdiagnosis. Improvements in sequencing technology are increasing opportunities to diagnose monogenic diabetes, but challenges remain. In this Review, we describe the types of monogenic diabetes, including common and uncommon types of maturity-onset diabetes of the young, multiple causes of neonatal DM, and syndromic diabetes such as Wolfram syndrome and lipodystrophy. We also review methods of prioritizing patients undergoing genetic testing, and highlight existing challenges facing sequence data interpretation that can be addressed by forming collaborations of expertise and by pooling cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W. W., Hegde, M., Lyon, E., Spector, E., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.30 · Cited by 32,594
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants
Ioannidis, N. M., Rothstein, J. H., Pejaver, V., Middha, S., McDonnell, S. K., Baheti, S., Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.08.016 · Cited by 2,908
Gloyn, A. L., Pearson, E. R., Antcliff, J. F., Proks, P., Bruining, G. J., Slingerland, A. S., Howard, N., Srinivasan, S., Silva, J. M. C. L., Molnes, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032922 · Cited by 1,137
Self-citationSwitching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · cited 1×
“1172/JCI142244 patients could switch from insulin therapy to sulfonylurea successfully (79, 83), with mutation severity (77, 84, 85) and diabetes duration before the transition (86) predicting the likelihood of success.”
BackgroundActivating Mutations in the ABCC8 Gene in Neonatal Diabetes Mellitus
Babenko, A. P., Polak, M., Cavé, H., Busiah, K., Czernichow, P., Scharfmann, R., Bryan, J., Aguilar-Bryan, L., Vaxillaire, M., & Froguel, P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055068 · Cited by 655 · cited 2×
“Whether variants will cause PNDM or TNDM (or, rarely, MODY) is determined in part by the functional severity of the mutation as well as which gene is involved, with KCNJ11 variants mainly associated with PNDM and most ABCC8 variants linked to TNDM (51, 69).”
BackgroundGenetic cause of hyperglycaemia and response to treatment in diabetes
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., & Hattersley, A. T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14571-0 · Cited by 607
Insulin gene mutations as a cause of permanent neonatal diabetes
Støy, J., Edghill, E. L., Flanagan, S. E., Ye, H., Paz, V. P., Pluzhnikov, A., Below, J. E., Hayes, M. G., Cox, N. J., Lipkind, G. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707291104 · Cited by 564
Clinical implications of a molecular genetic classification of monogenic β-cell diabetes
Murphy, R., Ellard, S., & Hattersley, A. T. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0778 · Cited by 502 · cited 1×
“1172/JCI142244 most MODY cases and the increased frequency of pediatric T2D due to increased childhood overweight and obesity prevalence, it has been suggested that this term be abandoned in favor of terms describing the etiology of the type of diabetes, such as transcription factor diabetes for MODY caused by mutatio…”
BackgroundInsulin Mutation Screening in 1,044 Patients With Diabetes
Edghill, E. L., Flanagan, S. E., Patch, A.-M., Boustred, C., Parrish, A., Shields, B., Shepherd, M. H., Hussain, K., Kapoor, R. R., Malecki, M., et al. (2008) · Diabetes · doi:10.2337/db07-1405 · Cited by 397
De Franco, E., Flanagan, S. E., Houghton, J. A., Allen, H. L., Mackay, D. J., Temple, I. K., Ellard, S., & Hattersley, A. T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60098-8 · Cited by 349
Hattersley, A. T., Greeley, S. A. W., Polak, M., Rubio-Cabezas, O., Njølstad, P. R., Mlynarski, W., Castano, L., Carlsson, A., Raile, K., Chi, D. V., et al. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12772 · Cited by 319 · cited 3×
“Though the majority of patients diagnosed between 6 and 12 months have T1D, NDM can exist in these patients; genetic testing should be considered if they test negative for autoantibody, have extrapancreatic features, or have unusual family history (1, 2).”
BackgroundAssociation of a Low-Frequency Variant in HNF1A With Type 2 Diabetes in a Latino Population
Estrada, K., Aukrust, I., Bjørkhaug, L., Burtt, N. P., Mercader, J. M., García-Ortiz, H., Huerta-Chagoya, A., Moreno-Macías, H., Walford, G., Flannick, J., et al. (2014) · JAMA · doi:10.1001/jama.2014.6511 · Cited by 259
Pearson, E. R., Liddell, W. G., Shepherd, M., Corrall, R. J., & Hattersley, A. T. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00305.x · Cited by 259
Prospective functional classification of all possible missense variants in PPARG
UK Monogenic Diabetes Consortium, Majithia, A. R., Myocardial Infarction Genetics Consortium, UK Congenital Lipodystrophy Consortium, Tsuda, B., Agostini, M., Gnanapradeepan, K., Rice, R., Peloso, G., Patel, K. A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3700 · Cited by 227 · cited 1×
“This approach encourages high-throughput mutation screenings, such as saturation mutagenesis (136) and systematic functional profiling of variants identified in the population (137, 138), which consist of pathogenic and benign variants.”
BackgroundRecessive mutations in the INS gene result in neonatal diabetes through reduced insulin biosynthesis
Garin, I., Edghill, E. L., Akerman, I., Rubio-Cabezas, O., Rica, I., Locke, J. M., Maestro, M. A., Alshaikh, A., Bundak, R., del Castillo, G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910533107 · Cited by 211
New insights into KATP channel gene mutations and neonatal diabetes mellitus
Pipatpolkai, T., Usher, S., Stansfeld, P. J., & Ashcroft, F. M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0351-y · Cited by 122 · cited 1×
“The benefit of identifying patients with KATPdiabetes is thus considerable, and many studies have attempted to establish genotype-phenotype correlation (67) to facilitate the prediction of patients’ clinical courses based on genetic data.”
BackgroundCarlsson, A., Shepherd, M., Ellard, S., Weedon, M., Lernmark, Å., Forsander, G., Colclough, K., Brahimi, Q., Valtonen-Andre, C., Ivarsson, S. A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0747 · Cited by 111 · cited 1×
“The Swedish Better Diabetes Diagnosis (BDD) study showed that absence of glutamic acid decarboxylase (GAD), islet antigen-2, zinc transporter 8 antibodies, and insulin autoantibodies could be a good discriminator, since in this study, MODY patients were only identified from the antibody-negative group, and 15% of anti…”
BackgroundSelf-citationNeonatal Diabetes and the K ATP Channel: From Mutation to Therapy
Ashcroft, F. M., Puljung, M. C., & Vedovato, N. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.02.003 · Cited by 106
High-sensitivity CRP discriminates HNF1A-MODY from other subtypes of diabetes
McDonald, T. J., Shields, B. M., Lawry, J., Owen, K. R., Gloyn, A. L., Ellard, S., & Hattersley, A. T. (2011) · Diabetes Care · doi:10.2337/dc11-0323 · Cited by 105
Self-citationCarmody, D., Naylor, R. N., Bell, C. D., Berry, S., Montgomery, J. T., Tadie, E. C., Hwang, J. L., Greeley, S. A. W., & Philipson, L. H. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0859-8 · Cited by 84 · cited 1×
“GCK-hyperglycemia has limited phenotypic heterogeneity; most patients have lifelong mild, persistent, and asymptomatic fasting hyperglycemia within the prediabetes range (27), with hemoglobin A1c values not exceeding 7.”
Background
Cited by
Phenotypic complexities of rare heterozygous neurexin-1 deletions
Fernando, M. B., Fan, Y., Zhang, Y., Tokolyi, A., Murphy, A. N., Kammourh, S., Deans, P. J. M., Ghorbani, S., Onatzevitch, R., Pero, A., et al. (2025) · Nature · doi:10.1038/s41586-025-08864-9 · Cited by 30
Structural properties of the HNF-1A transactivation domain
Kind, L., Driver, M., Raasakka, A., Onck, P. R., Njølstad, P. R., Arnesen, T., & Kursula, P. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1249939 · Cited by 10
Steenkamp, D. W., Cheney, M. C., Ju, Z., Rodbard, D., & Wolpert, H. A. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad038 · Cited by 7
Metadata
- Authors
- Zhang, H., Colclough, K., Gloyn, A. L., & Pollin, T. I.
- Venue
- Journal of Clinical Investigation
- Published
- 2021-02-01
- Volume
- 131
- Issue
- 3
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3127261530
- Cited by
- 188
- References
- 22
- FWCI
- 14.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.